Clinical Trial

ENA-001 for Opioid Induced Respiratory Depression

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a Phase I clinical trial to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles with single intravenous (IV) and intramuscular (IM) doses of ENA-001.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-05-09
Trial Details
NCT Number NCT06967259
Lead Sponsor Enalare Therapeutics Inc.
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Respiratory Depression
Enrollment 36 participants
Start Date 2025-05-14
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-08